Navigation Links
Roche clinical trial registry and results database launched

Within only three months after deciding to create an electronic database, Roche is launching a public clinical trial registry and results database using an independent host, CenterWatch. On www.roche-trials.com information on Roche’s clinical trials can be accessed by anyone, anywhere, with no password restrictions. This site is designed to give patients and healthcare providers ready access to information they need, in terms they can understand.

Ed Holdener, Head of Global Pharma Development at Roche, said: “We are proud to go live with our publicly accessible protocol registry and clinical trial results database today. Transparency has always been and continues to be a priority for us. In January, we announced our plans to have an independent host for the database and since then, we selected CenterWatch, a company with a wealth of experience in the area of data management and the publication of clinical trial information. So for the first time ever, there is now a global and publicly accessible database, containing comprehensive information about Roche’s clinical trials?

Roche expects that the huge task of publishing data from more than 30 medicines, on a product by product level from a large number of global and local trials, will take approximately a year. Roche will also continue to contribute information to established databases (i.e. www.clinicaltrials.gov)

Information that can be found in the electronic database
Starting with Fuzeon and Bondronat, clinical trial information will be added in a staged approach on the databases and will ultimately include protocol information and results from all Phase II to Phase IV clinical trials completed after 1 October, 2004. In addition, data from all Phase II to Phase IV clinical trials for medicines first marketed after 1 October, 2002 will be included retrospectively. The clinical trial registry and results database will also include interventional clinical studies from Roche Diagnostics.< /p>

Roche approach and possible industry solution
Roche is taking a leadership role in the industry’s efforts to ensure transparency with its global approach, which is consistent with the information disclosure principles published earlier this year by the European Federation of Pharmaceutical Industry Associations (EFPIA).
The Roche strategy may model an industry-wide solution. Roche would support and participate in a future industry solution that provides a public database in which all companies can publish both national and international protocol information and trial results. Roche would be delighted if this independent solution would lead other pharmaceutical companies to use the CenterWatch repository to register ongoing clinical trials and report results of trials.
CenterWatch is a leader in web design and experienced in the implementation of websites for clinical trial listings and clinical trial results, and already has an established reputation as an independent source that the public trusts for clinical trial listings and results. Having CenterWatch host Roche’s clinical trials databases provides the widest possible exposure, and makes it easy for the public to obtain important information in this area.

Strict adherence to regulations of clinical trials
Roche works to ensure that all its activities are performed in accordance with ethical and regulatory requirements. Moreover, Roche is strongly committed to verifying adherence to compliance policies. Adequate and ongoing peer review is a key prerequisite for maintaining high ethical standards in Roche’s clinical trials and development activities.
In addition, Roche adheres to the “Declaration of Helsinki? a statement developed by the World Medical Association on ethical principles to provide guidance to physicians and other participants in medical research involving human subjects. Roche also strictly follows the rules of good clinical practice (GCP), which ensure the protection of patients?safety and rights.


'"/>

Source:Roche


Related biology news :

1. Rochester scientists develop fast-working biosensor
2. NIAID begins clinical trial of West Nile virus vaccine
3. Compound might defeat African sleeping sickness, clinical trial beginning this month
4. Neurologix announces positive results of gene therapy clinical trial in Parkinsons disease
5. Dalai Lama, top scientists to discuss science & clinical applications of meditation
6. Stem cells electric abilities might help their safe clinical use
7. New malaria vaccine shows promise in early clinical trial
8. Preclinical study of a new brain tumor therapy
9. Tramiprosate (Alzhemed? preclinical results published in Neurobiology of Aging
10. Fatty spheres loaded with siRNA shrink ovarian cancer tumors in preclinical trial
11. NIH announces phase III clinical trial of creatine for Parkinsons disease
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/7/2017)... 2017   MedNet Solutions , an innovative SaaS-based ... clinical research, is pleased to announce that the latest ... highly flexible and award winning eClinical solution, is now ... is a proven Software-as-a-Service (SaaS) clinical research technology ... but also delivers an entire suite of eClinical tools ...
(Date:2/7/2017)... 2017 Ipsidy Inc. ( www.ipsidy.com ... IDGS], ("Ipsidy" or the "Company") a provider of secure, ... is pleased to announce the following changes as part ... January 31, 2017, Philip D. Beck was ... President.  An experienced payment industry professional and public company ...
(Date:2/3/2017)... , Feb. 3, 2017  Texas Biomedical Research Institute ... Larry Schlesinger as the Institute,s new President ... Biomed effective May 31, 2017. He is currently the Chair ... of the Center for Microbial Interface Biology at Ohio State ... as the new President and CEO of Texas Biomed," said ...
Breaking Biology News(10 mins):
(Date:2/15/2017)...  Trianni, Inc. („TRIANNI") gab heute bekannt, man ... über die Verwendung der The Trianni Mouse unterschrieben, ... Entdeckung monoklonaler Antikörper. Die Trianni Plattform ... das Janssen den Zugang zu einer ... für die schelle Isolierung vollständig menschlicher Therapeutika optimiert ...
(Date:2/15/2017)... 2017  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), ... fourth quarter and full year ended December 31, ... for Vanda as we continued to demonstrate strong ... exclusivity for Fanapt," said Mihael H. Polymeropoulos, M.D., ... pipeline with important 2017 milestones underscores Vanda,s commitment ...
(Date:2/15/2017)... Feb. 15, 2017 Windtree Therapeutics, Inc. (Nasdaq: ... developing aerosolized KL4 surfactant therapies for respiratory diseases, will ... presentation) at 8:00 AM EST on Thursday, February 16, ... clinical program, the recently announced closing of a $10.5 ... To participate in the live call and ...
(Date:2/15/2017)... ... February 15, 2017 , ... Diameter Health ... Diameter Health technology in the hands of Lantana analysts. The high-performance platform of ... and public health entities – all those mining value from clinical data – ...
Breaking Biology Technology: